-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, G7Qa5xNBuc5yu4AWXmvsVo06lOWiDZvoNDtzHvj752UiJBkDEE7xvjY4dBOibs7q K6YyiSMcclD6eirl2nq15g== 0001181431-09-031663.txt : 20090619 0001181431-09-031663.hdr.sgml : 20090619 20090619203259 ACCESSION NUMBER: 0001181431-09-031663 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090617 FILED AS OF DATE: 20090619 DATE AS OF CHANGE: 20090619 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584526600 MAIL ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24274 FILM NUMBER: 09902323 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 rrd246508.xml FORM 4 X0303 4 2009-06-17 1 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001048477 BIOMARIN PHARMACEUTICAL INC 105 DIGITAL DRIVE NOVATO CA 94949 0 0 1 0 Common Stock 2009-06-17 4 S 0 960950 0.2248 D 9212170 D Common Stock 2009-06-18 4 S 0 2198825 0.2096 D 7013345 D Common Stock 2009-06-19 4 S 0 2546958 0.2059 D 4466387 D This transaction was executed in multiple trades at prices ranging from $0.22 to $0.2403. The reported price reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission ("SEC") staff, the Issuer or a shareholder of the Issuer full information regarding the number of shares purchased at each separate price. This transaction was executed in multiple trades at prices ranging from $0.20 to $0.2248. The reported price reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request by the SEC staff, the Issuer or a shareholder of the Issuer full information regarding the number of shares purchased at each separate price. This transaction was executed in multiple trades at prices ranging from $0.20 to $0.2201. The reported price reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request by the SEC staff, the Issuer or a shareholder of the Issuer full information regarding the number of shares purchased at each separate price. /s/ G. Eric Davis, Vice President, General Counsel 2009-06-19 -----END PRIVACY-ENHANCED MESSAGE-----